Literature DB >> 19881887

Spectroscopic and Thermal Characterization of the Host-Guest Interactions between α-, β-, and γ-cyclodextrins and vanadocene dichloride.

Alexis Morales1, Ralph T Weber, Enrique Melendez.   

Abstract

Host-guest interactions between α-, β-, and γ-cyclodextrins and vanadocene dichloride (Cp(2)VCl(2)) have been investigated by a combination of thermogravimetric analysis, differential scanning calorimeters, PXRD and solid state and solution EPR spectroscopy. The solid state results demonstrated that only β- and γ-cyclodextrins form 1:1 inclusion complexes, while α-cyclodextrin does not form an inclusion complex with Cp(2)VCl(2). The β- and γ-CD-Cp(2)VCl(2) inclusion complexes exhibited anisotropic electron-(51)V (I = 7/2) hyperfine coupling constants whereas the α-CD- Cp(2)VCl(2) system showed only an asymmetric peak with no anisotropic hyperfine constant. On the other hand, solution EPR spectroscopy showed that α-CD may be involved in weak host-guest interactions in equilibrium with free vanadocene species.

Entities:  

Year:  2008        PMID: 19881887      PMCID: PMC2770188          DOI: 10.1002/aoc.1420

Source DB:  PubMed          Journal:  Appl Organomet Chem        ISSN: 0268-2605            Impact factor:   4.105


  10 in total

1.  Titanocene dichloride--the first metallocene with cancerostatic activity.

Authors:  H Köpf; P Köpf-Maier
Journal:  Angew Chem Int Ed Engl       Date:  1979-06       Impact factor: 15.336

Review 2.  Cyclodextrins as supramolecular hosts for organometallic complexes.

Authors:  F Hapiot; S Tilloy; E Monflier
Journal:  Chem Rev       Date:  2006-03       Impact factor: 60.622

3.  Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.

Authors:  P Köpf-Maier; H Köpf
Journal:  Naturwissenschaften       Date:  1980-08

4.  [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].

Authors:  P Köpf-Maier; B Hesse; H Köpf
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

Review 5.  Antitumour metallocenes: structure-activity studies and interactions with biomolecules.

Authors:  M M Harding; G Mokdsi
Journal:  Curr Med Chem       Date:  2000-12       Impact factor: 4.530

6.  Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.

Authors:  C V Christodoulou; D R Ferry; D W Fyfe; A Young; J Doran; T M Sheehan; A Eliopoulos; K Hale; J Baumgart; G Sass; D J Kerr
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  In vitro activity of titanocenedichloride versus cisplatin in four ovarian carcinoma cell lines evaluated by a microtiter plate ATP bioluminescence assay.

Authors:  C M Kurbacher; H W Bruckner; P E Andreotti; J A Kurbacher; G Sass; D Krebs
Journal:  Anticancer Drugs       Date:  1995-10       Impact factor: 2.248

8.  Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride.

Authors:  C Villena-Heinsen; M Friedrich; A K Ertan; C Farnhammer; W Schmidt
Journal:  Anticancer Drugs       Date:  1998-07       Impact factor: 2.248

Review 9.  Titanium complexes in cancer treatment.

Authors:  Enrique Meléndez
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

Review 10.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  10 in total
  2 in total

1.  Host-Guest Interactions between Calixarenes and Cp(2)NbCl(2).

Authors:  Alexis Morales; Alberto Santana; Gerhard Althoff; Enrique Melendez
Journal:  J Organomet Chem       Date:  2011-07-01       Impact factor: 2.369

2.  Titanocene / cyclodextrin supramolecular systems: a theoretical approach.

Authors:  Adrian Riviş; Nicoleta G Hădărugă; Zeno Gârban; Daniel I Hădărugă
Journal:  Chem Cent J       Date:  2012-11-05       Impact factor: 4.215

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.